|
|
|
Volumn 24, Issue 10, 2010, Pages
|
|
Dendreon vs CMS: Why the provenge coverage controversy is bigger than just one product
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BEVACIZUMAB;
DOCETAXEL;
IBRITUMOMAB TIUXETAN;
PROVENGE;
RITUXIMAB;
TRASTUZUMAB;
BIOTECHNOLOGICAL PRODUCTION;
CANCER CHEMOTHERAPY;
CANCER IMMUNOTHERAPY;
CANCER PATIENT;
CELL THERAPY;
COST EFFECTIVENESS ANALYSIS;
DRUG INDUSTRY;
FOOD AND DRUG ADMINISTRATION;
GOVERNMENT;
MEDICARE;
PROSTATE CANCER;
SHORT SURVEY;
|
|
EID: 77958566305
PISSN: 08909091
EISSN: 08909091
Source Type: Journal
DOI: None Document Type: Short Survey |
|
Times cited : (3)
|
|
References (0)
|
